| |
| |
|
| Insider
Information: |
Cassella James V |
| Relationship: |
Chief Development Offi... |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
62,495 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
62,495 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alexza Pharmaceuticals Inc. |
ALXA |
EVP, R&D and CSO |
2013-03-29 |
62,495 |
2009-02-24 |
0 |
Premium* |
|
|
Concert Pharmaceuticals, Inc. |
CNCE |
Chief Development Offi... |
2023-03-06 |
0 |
2017-07-06 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2023-03-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(57,766) |
0 |
0 |
- |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2023-03-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(80,595) |
0 |
0 |
- |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2023-02-15 |
4 |
AS |
$8.34 |
$31,375 |
D/D |
(3,762) |
173,061 |
0 |
% |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2023-01-30 |
4 |
AS |
$8.35 |
$84,385 |
D/D |
(10,106) |
176,823 |
0 |
% |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2023-01-06 |
4 |
AS |
$7.25 |
$20,974 |
D/D |
(2,893) |
186,929 |
0 |
% |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2022-02-14 |
4 |
AS |
$3.09 |
$11,625 |
D/D |
(3,762) |
189,822 |
0 |
% |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2022-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
110,500 |
193,584 |
0 |
- |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2022-01-05 |
4 |
AS |
$3.19 |
$9,232 |
D/D |
(2,894) |
83,084 |
0 |
% |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2021-08-16 |
4 |
AS |
$3.28 |
$26,522 |
D/D |
(8,086) |
85,978 |
0 |
% |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2021-02-16 |
4 |
AS |
$7.32 |
$27,545 |
D/D |
(3,763) |
94,064 |
0 |
% |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2021-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
21,700 |
97,827 |
0 |
- |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2020-08-17 |
4 |
AS |
$10.37 |
$45,151 |
D/D |
(4,354) |
76,127 |
0 |
% |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2020-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
28,216 |
80,481 |
0 |
- |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2019-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
31,100 |
52,265 |
0 |
- |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2019-03-31 |
4 |
D |
$12.07 |
$106,638 |
D/D |
(8,835) |
21,165 |
0 |
- |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2018-04-17 |
4 |
AS |
$20.18 |
$213,510 |
D/D |
(10,582) |
30,000 |
0 |
- |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2018-03-31 |
4/A |
D |
$22.90 |
$101,172 |
D/D |
(4,418) |
40,582 |
0 |
- |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2018-03-31 |
4 |
D |
$22.90 |
$101,172 |
D/D |
(4,418) |
55,582 |
0 |
- |
|
| CNCE |
Concert Pharmaceuticals, ... |
Chief Development Officer |
• – – |
2017-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
60,000 |
0 |
- |
|
| ALXA |
Alexza Pharmaceuticals In... |
EVP, R&D and CSO |
• – – |
2013-03-29 |
4 |
A |
$4.42 |
$193,375 |
D/D |
43,750 |
62,495 |
0 |
- |
|
| ALXA |
Alexza Pharmaceuticals In... |
EVP, R&D and CSO |
• – – |
2013-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
17,795 |
18,745 |
0 |
- |
|
| ALXA |
Alexza Pharmaceuticals In... |
EVP, R&D and CSO |
• – – |
2012-12-26 |
4 |
AS |
$4.90 |
$22,316 |
D/D |
(4,558) |
950 |
0 |
- |
|
| ALXA |
Alexza Pharmaceuticals In... |
EVP, R&D and CSO |
• – – |
2012-08-27 |
4 |
AS |
$4.14 |
$41,364 |
D/D |
(10,000) |
5,508 |
0 |
- |
|
| ALXA |
Alexza Pharmaceuticals In... |
SVP, Research & Development |
• – – |
2012-06-06 |
4 |
AS |
$0.34 |
$15,628 |
D/D |
(46,222) |
157,801 |
0 |
- |
|
| ALXA |
Alexza Pharmaceuticals In... |
SVP, Research & Development |
• – – |
2012-03-23 |
4 |
A |
$0.00 |
$0 |
D/D |
46,222 |
104,023 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
